Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Interim PET-CT-guided therapy in elderly patients with Hodgkin lymphoma-a retrospective national multi-center study.

Bentur OS, Dann EJ, Paran E, Lavie D, Nachmias B, Ron Y, Dally N, Gutwein O, Herishanu Y, Sarid N, Avivi I, Perry C.

Ann Hematol. 2019 Jul;98(7):1665-1674. doi: 10.1007/s00277-019-03686-y. Epub 2019 May 18.

PMID:
31104090
2.

Results from HARMONY: an open-label, multicenter, 2-arm, phase 1b, dose-finding study assessing the safety and efficacy of the oral combination of ruxolitinib and buparlisib in patients with myelofibrosis.

Durrant ST, Nagler A, Guglielmelli P, Lavie D, le Coutre P, Gisslinger H, Chuah C, Maffioli M, Bharathy S, Dong T, Wroclawska M, Lopez JM.

Haematologica. 2019 Dec;104(12):e551-e554. doi: 10.3324/haematol.2018.209965. Epub 2019 May 9. No abstract available.

3.

Romidepsin-Bendamustine Combination for Relapsed/Refractory T Cell Lymphoma.

Nachmias B, Shaulov A, Lavie D, Goldschmidt N, Gural A, Saban R, Lebel E, Gatt ME.

Acta Haematol. 2019;141(4):216-221. doi: 10.1159/000498905. Epub 2019 Apr 3.

PMID:
30943470
4.

Duodenal amyloid A depositions in a patient with refractory Hodgkin's lymphoma: an old complication in the modern treatment era.

Shaulov A, Prus D, Lavie D, Elias S.

Amyloid. 2018 Dec;25(4):263-264. doi: 10.1080/13506129.2018.1517737. Epub 2018 Oct 23. No abstract available.

PMID:
30350721
5.

Two Cases and a Review of Graft-Versus-Host Disease and the Role of Hepatitis C Treatment in Liver Transplant Patients.

Advani SD, Nellore A, Hadjivassiliou G, Eckhoff DE, Salzman D, Lavie D, Pavlidakey P, Baddley JW.

Prog Transplant. 2018 Sep;28(3):267-270. doi: 10.1177/1526924818781558. Epub 2018 Jun 28.

PMID:
29954253
6.

Real-life Experience With Ponatinib in Chronic Myeloid Leukemia: A Multicenter Observational Study.

Shacham-Abulafia A, Raanani P, Lavie D, Volchek Y, Ram R, Helman I, Shargian L, Gourevitch A, Chubar E, Ratzon R, Rozovski U.

Clin Lymphoma Myeloma Leuk. 2018 Jul;18(7):e295-e301. doi: 10.1016/j.clml.2018.05.002. Epub 2018 May 7.

PMID:
29773429
7.

Daratumumab resistance is frequent in advanced-stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosis.

Pick M, Vainstein V, Goldschmidt N, Lavie D, Libster D, Gural A, Grisariu S, Avni B, Ben Yehuda D, Gatt ME.

Eur J Haematol. 2018 May;100(5):494-501. doi: 10.1111/ejh.13046. Epub 2018 Mar 25.

PMID:
29453884
8.

Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.

Harrison CN, Vannucchi AM, Platzbecker U, Cervantes F, Gupta V, Lavie D, Passamonti F, Winton EF, Dong H, Kawashima J, Maltzman JD, Kiladjian JJ, Verstovsek S.

Lancet Haematol. 2018 Feb;5(2):e73-e81. doi: 10.1016/S2352-3026(17)30237-5. Epub 2017 Dec 20.

PMID:
29275119
9.

Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET/CT is beneficial: a prospective multicentre trial of 355 patients.

Dann EJ, Bairey O, Bar-Shalom R, Mashiach T, Barzilai E, Kornberg A, Akria L, Tadmor T, Filanovsky K, Abadi U, Kagna O, Ruchlemer R, Abdah-Bortnyak R, Goldschmidt N, Epelbaum R, Horowitz NA, Lavie D, Ben-Yehuda D, Shpilberg O, Paltiel O.

Br J Haematol. 2017 Sep;178(5):709-718. doi: 10.1111/bjh.14734. Epub 2017 Jun 7.

PMID:
28589704
10.

Factors related to the development of acquired von Willebrand syndrome in patients with essential thrombocythemia and polycythemia vera.

Rottenstreich A, Kleinstern G, Krichevsky S, Varon D, Lavie D, Kalish Y.

Eur J Intern Med. 2017 Jun;41:49-54. doi: 10.1016/j.ejim.2016.11.011. Epub 2016 Dec 2.

PMID:
27919526
11.

Progressive refractory light chain amyloidosis and multiple myeloma patients are responsive to the addition of clarithromycin to IMiD based therapy.

Shaulov A, Ganzel C, Benyamini N, Barshay Y, Goldschmidt N, Lavie D, Libster D, Gural A, Avni B, Gatt ME.

Am J Hematol. 2017 Feb;92(2):131-135. doi: 10.1002/ajh.24596. Epub 2016 Nov 21.

12.

Inside Out: Bone Marrow Necrosis and Fat Embolism Complicating Sickle-╬▓+ Thalassemia.

May J, Sullivan JC, LaVie D, LaVie K, Marques MB.

Am J Med. 2016 Dec;129(12):e321-e324. doi: 10.1016/j.amjmed.2016.05.027. Epub 2016 Jun 11. No abstract available.

PMID:
27296331
13.

Favorable outcome of primary mediastinal large B-cell lymphoma patients treated with sequential RCHOP-RICE regimen without radiotherapy.

Goldschmidt N, Kleinstern G, Orevi M, Paltiel O, Ben-Yehuda D, Gural A, Libster D, Lavie D, Gatt ME.

Cancer Chemother Pharmacol. 2016 May;77(5):1053-60. doi: 10.1007/s00280-016-3024-8. Epub 2016 Apr 7.

PMID:
27056383
14.

Ruxolitinib treatment for myelofibrosis: Efficacy and tolerability in routine practice.

Ellis MH, Lavi N, Mishchenko E, Dally N, Lavie D, Courevitch A, Gutwein O, Bulvik S, Braester A, Chubar E, Tavor S, Duek A, Kirgner I, Koren-Michowitz M.

Leuk Res. 2015 Aug 12. pii: S0145-2126(15)30356-8. doi: 10.1016/j.leukres.2015.08.003. [Epub ahead of print]

PMID:
26364797
15.

A Randomized Controlled Study to Determine the Efficacy of Garlic Compounds in Patients With Hematological Malignancies at Risk for Chemotherapy-Related Febrile Neutropenia.

Gatt ME, Strahilevitz J, Sharon N, Lavie D, Goldschmidt N, Kalish Y, Gural A, Paltiel OB.

Integr Cancer Ther. 2015 Sep;14(5):428-35. doi: 10.1177/1534735415588928. Epub 2015 Jun 2.

PMID:
26036623
16.

Polymorphisms in the human organic cation transporter and the multidrug resistance gene: correlation with imatinib levels and clinical course in patients with chronic myeloid leukemia.

Vine J, Cohen SB, Ruchlemer R, Goldschmidt N, Levin M, Libster D, Gural A, Gatt ME, Lavie D, Ben-Yehuda D, Rund D.

Leuk Lymphoma. 2014 Nov;55(11):2525-31. doi: 10.3109/10428194.2014.893307. Epub 2014 Mar 19.

PMID:
24524306
17.

Bortezomib-induced peripheral neuropathy is related to altered levels of brain-derived neurotrophic factor in the peripheral blood of patients with multiple myeloma.

Azoulay D, Lavie D, Horowitz N, Suriu C, Gatt ME, Akria L, Perlman R, Braester A, Ben-Yehuda D.

Br J Haematol. 2014 Feb;164(3):454-6. doi: 10.1111/bjh.12624. Epub 2013 Oct 25. No abstract available.

PMID:
24164472
18.

Trends and distribution of oral and pharyngeal lymphoma in Israel.

Zini A, Atia-Joachim D, Sgan-Cohen HD, Lavie D, Czerninski R.

Oral Dis. 2012 Oct;18(7):700-6. doi: 10.1111/j.1601-0825.2012.01928.x. Epub 2012 Apr 5.

PMID:
22486996
19.

Chompy: an infestation of MITE-like repetitive elements in the crocodilian genome.

Ray DA, Hedges DJ, Herke SW, Fowlkes JD, Barnes EW, LaVie DK, Goodwin LM, Densmore LD, Batzer MA.

Gene. 2005 Dec 5;362:1-10. Epub 2005 Sep 23.

PMID:
16183215
20.

Hypericin as an inactivator of infectious viruses in blood components.

Lavie G, Mazur Y, Lavie D, Prince AM, Pascual D, Liebes L, Levin B, Meruelo D.

Transfusion. 1995 May;35(5):392-400.

PMID:
7740610
21.

The chemical and biological properties of hypericin--a compound with a broad spectrum of biological activities.

Lavie G, Mazur Y, Lavie D, Meruelo D.

Med Res Rev. 1995 Mar;15(2):111-9. Review. No abstract available. Erratum in: Med Res Rev 1995 May;15(3):259.

PMID:
7739292
22.

Inactivation of the human immunodeficiency virus by hypericin: evidence for photochemical alterations of p24 and a block in uncoating.

Degar S, Prince AM, Pascual D, Lavie G, Levin B, Mazur Y, Lavie D, Ehrlich LS, Carter C, Meruelo D.

AIDS Res Hum Retroviruses. 1992 Nov;8(11):1929-36.

PMID:
1283309
23.

A method for the quantitation of hypericin, an antiviral agent, in biological fluids by high-performance liquid chromatography.

Liebes L, Mazur Y, Freeman D, Lavie D, Lavie G, Kudler N, Mendoza S, Levin B, Hochster H, Meruelo D.

Anal Biochem. 1991 May 15;195(1):77-85.

PMID:
1888019
24.

Studies of the mechanisms of action of the antiretroviral agents hypericin and pseudohypericin.

Lavie G, Valentine F, Levin B, Mazur Y, Gallo G, Lavie D, Weiner D, Meruelo D.

Proc Natl Acad Sci U S A. 1989 Aug;86(15):5963-7.

26.
27.

Immunosuppressive activity of two plant steroidal lactones withaferin A and withanolide E.

Shohat B, Kirson I, Lavie D.

Biomedicine. 1978 Jan-Feb;28(1):18-24.

PMID:
27256
28.

1-Oxo-steroids. Part 2. Model studies for the synthesis of the withanolides.

Weissenberg M, Lavie D, Glotter E.

J Chem Soc Perkin 1. 1977;(7):795-801. No abstract available.

PMID:
558220
30.

Structure and stereochemistry of cyclobutatusin, a diterpenoid containing a four-membered ring.

Wang AH, Paul IC, Zelnik R, Lavie D, Levy EC.

J Am Chem Soc. 1974 Jan 23;96(2):580-1. No abstract available.

PMID:
4815366
31.

Antifertility activity of dihydroelatericin A in the female mouse.

Shohat B, Beemer AM, Gitter S, Lavie D.

Experientia. 1972 Oct 15;28(10):1203-5. No abstract available.

PMID:
5087040
32.

Quaternary pilocarpine derivatives acting as acetylcholine antagonists.

Bassat AB, Lavie D, Edery H, Porath G.

J Med Chem. 1971 Nov;14(11):1066-9. No abstract available.

PMID:
5115205
33.

The cucurbitanes, a group of tetracyclic triterpenes.

Lavie D, Glotter E.

Fortschr Chem Org Naturst. 1971;29:307-62. Review. No abstract available.

PMID:
4949442
34.

Effect of withaferin A on Ehrlich ascites tumor cells--cytological observations.

Shohat B, Gitter S, Lavie D.

Int J Cancer. 1970 Mar 15;5(2):244-52. No abstract available.

PMID:
5449164
35.

Studies on strychnine derivatives and conversion into brucine.

Tedeschi E, Dukler S, Pfeffer P, Lavie D.

Tetrahedron. 1968 Jun;24(12):4573-80. No abstract available.

PMID:
5655289
36.

Antitumor activity of withaferin A (NSC-101088).

Shohat B, Gitter S, Abraham A, Lavie D.

Cancer Chemother Rep. 1967 Sep;51(5):271-6. No abstract available.

PMID:
6062297
37.

Action of elatericin A on human leukemic and normal lymphocytes.

Shohat B, Gitter S, Lavie D.

J Natl Cancer Inst. 1967 Jan;38(1):1-9. No abstract available.

PMID:
6071237
38.

The combined effect of cucurbitacins and X-ray treatment on transplanted tumors in mice.

Shohat B, Gitter S, Levie B, Lavie D.

Cancer Res. 1965 Nov;25(10):1828-35. No abstract available.

39.

THE CONSTITUENTS OF ECBALLIUM ELATERIUM L. XXI. ISOMERISM IN RING A OF THE CUCURBITANES.

LAVIE D, BENJAMINOV BS.

J Org Chem. 1965 Feb;30:607-10. No abstract available.

PMID:
14267303
40.

Antitumor activity of cucurbitacins: metabolic aspects.

SHOHAT B, GITTER S, LAVIE D.

Cancer Chemother Rep. 1962 Oct;23:19-24. No abstract available.

PMID:
13988643
41.

Further studies on the antitumor effect of cucurbitacins.

GALLILY R, SHOHAT B, KALISH J, GITTER S, LAVIE D.

Cancer Res. 1962 Oct;22:1038-45. No abstract available.

42.

Studies on the antitumor effect of cucurbitacins.

GITTER S, GALLILY R, SHOHAT B, LAVIE D.

Cancer Res. 1961 May;21:516-21. No abstract available.

PMID:
13705788
43.

New compounds from plants with anti-tumor activity.

LAVIE D, WILLNER D, BELKIN M, HARDY WG.

Acta Unio Int Contra Cancrum. 1959;15(Suppl 1):177-81. No abstract available.

PMID:
14414656
44.

The functional groupings of alpha-elaterin (cucurbitacin E).

LAVIE D.

J Pharm Pharmacol. 1958 Dec;10(12):782. No abstract available.

PMID:
13611647

Supplemental Content

Support Center